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Abstract
Functionally selective ligands (also known as biased ligands) of dopamine D2 receptors have been considered as not only valuable tools for
dissecting the roles of D2-mediated G protein-dependent and independent signaling pathways, but also better antipsychotic drug candidates
for neurological and psychiatric disorders including schizophrenia. Consequently, functionally selective D2R ligands have also been increasingly
pursued by the biomedical community as promising antipsychotic therapeutics with improved efficacy and reduced side effects compared with
unbiased ligands. This review will discuss the recent development in the discovery of functional selective D2R ligands Figure 1.

Figure 1: Functional selective D2R ligands.

Introduction
Schizophrenia is a chronic and severe mental disorder
characterized by abnormal social behavior and failure to
understand reality [1]. Clinically, the disorder manifests with a
large variety of symptoms that fall into three categories: positive,
negative, and cognitive [2]. Schizophrenia affects about 1.1% of
world wide population [3]. Although schizophrenia is not as
common as other mental disorders such as anxiety disorder
(18.1%) [4], depression (6.9%) [5], and bipolar disorder (2.6%)
[6], the symptoms can be very disabling. Therefore, it is often
associated with high levels of morbidity and mortality [7]. The
average life expectancy of people with schizophrenia is ten to
twenty-five years less than for the general population [8]. This
is the result of increased physical health problems and a higher
suicide rate (about 10%) [9,10].
Although scientists believe that a combination of genetics,
environment, and altered brain chemistry and structure may
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play a role in the development of schizophrenia [11], the exact
cause of this disorder is still unknown to the research community.
Consequently, there is no cure for this disorder and treatments
have been focusing on eliminating the symptoms of the disease.
The primary treatment of schizophrenia is antipsychotic
medications [12], often in combination with psychological and
social supports. While the current FDA-approved antipsychotic
drugs are able to reduce the positive symptoms of schizophrenia
in about 7 to 14 days [13,14], they have limited efficacy with
negative and/or cognitive symptoms [15,16].
Furthermore, antipsychotic medications can greatly lower
the patients’ life quality by inducing a wide range of motor,
metabolic, cardiovascular, and emotional side effects which
also lead to treatment noncompliance [14,17]. Therefore, it is
of great necessity to develop novel pharmaco therapies which
have better efficacies for treating all three clinical schizophrenia
symptoms and possess a low profile for side effects.
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With all currently FDA-approved antipsychotic drugs
target primarily the dopamine D2 receptor (D2R) for their
reaction [15-18], it is indicated that opposing dopamine
signaling is central for alleviating psychotic symptoms with
schizophrenia [19]. Clinical observations have revealed that
schizophrenia-like symptoms occur in amphetamine abusers
due to excessive dopamine release [20]. Also baseline dopamine
levels and stimulated release of dopamine are found to be
abnormal in mesolimbic systems of brains from schizophrenic
patients [21]. All these evidences have put dopamine receptor,
especially dopamine D2R at the center for the development of
antipsychotic drug. Antagonists and partial agonists of D2R have
been extensively pursued as antipsychotic therapeutics for the
treatment of schizophrenia [22,23].
As a member in the big family of G protein-coupled receptors
(GPCR), dopamine D2 receptor (D2R) is Gαi/o coupled whose
activation inhibits CAMP production [24]. Antipsychotic drugs
targeting D2R were originally identified as being able to bind to
D2R and regulate CAMP synthesis [18]. Mounting evident from
recent studies indicate that D2R signal not only via canonical
pathway involving hetero trimeric large G protein, but also
via noncanonical G protein-independent pathways with other
signaling proteins including, most prominently, β-arrestins [2528]. Most antipsychotic drugs have been found to have both G
protein-dependant and G protein-independent actions [28].
The process by which GPCR ligands, including D2R ligands,
differentially modulate canonical and noncanonical signal
transduction pathways is a phenomenon known as “functional
selectivity” or “biased agonism” [29,30].
With functionally selective D2R ligands that can preferentially
activate either canonical or noncanonical D2 signaling pathways
[31,32], it is thus very clear that the D2R ligands with discrete
functional selectivity profiles will be extremely useful for
elucidating the key signal transduction pathways essential for
both the therapeutic actions and the side effects of antipsychotic
drugs [30]. And this understanding will in turn enable the design
of better antipsychotic drug candidates, which can ultimately
lead to safer and more effective therapies for schizophrenia
patients. In this short review article, we will summarize the
recent development in the discovery of functional selective D2R
ligands for the treatment of schizophrenia.

Functional Selective D2RLigands
Aripiprizole

Aripiprazole (OPC-14597, 1), an FDA-approved atypical
antipsychotic drug, was one of the first functionally selective D2R
ligands identified [31,33,34]. It has an excellent side-effect profile
presumed, in part, to be due to lack of typical D2R antagonist
properties. Although aripiprazole was initially described as a
partial D2R agonist, on the basis of assays performed in whole
animals and isolated tissues [35-37], it was later demonstrated
that aripiprazole could behave as a full agonist, a partial agonist,
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or an antagonist at D2R depending upon the signaling readout
and cell type interrogated [28,31,33,38].

The study examined D2R binding properties of aripiprazole
as well as the effects of the drug on three downstream D2Rmediated functional effectors including mitogen-activated
protein kinase (MAPK) phosphorylation, potentiation of
arachidonic acid (AA) release, and D2R internalization revealed
that aripiprazole affects D2L-mediated signaling pathways in a
differential manner [31]. In the study examining the properties
of aripiprazole at D2 like auto receptors by monitoring the
changes of dopamine synthesis in adult rat brain striatal minces
incubated ex vivo, it was found that alteration of dopaminergic
tone by depolarization affected the actions of aripiprazole on D₂like auto receptors [39].

The in vivo study aimed to investigate the effects of
aripiprazole on the D2R downstream cAMP-PKA and Akt-GSK3β
signaling pathways suggested that aripiprazole had differential
effects on the cAMP-PKA and Akt-GSK3β signaling pathways in
the brain areas [40]. Additional studies examined the activity
of aripiprazole in D2R-mediated heterologous sensitization of
adenylyl cyclase and cell-based dynamic mass redistribution
(DMR). Aripiprazole displayed a unique functional profile for
modulation of G proteins, being a partial agonist for Gαi/o and
a robust antagonist for Gβγ signaling. Additionally, aripiprazole
was a weak partial agonist for both heterologous sensitization
and dynamic mass redistribution [41].

UNC9975 (2), UNC0006 (3) and UNC9994 (4)

Through a robust diversity-oriented multi-dimensional
modification of the scaffold represented by aripiprazole (1), Three
β-arrestin-biased D2R ligands including UNC9975 (2), UNC0006
(3), and UNC9994 (4) were reported as the unprecedented
β-arrestin-biased ligands for a Gi-coupled G protein–coupled
receptor (GPCR) [42]. All three D2R ligands were simultaneously
antagonists of Gi-regulated CAMP production and partial
agonists for D2R/β-arrestin-2 interactions. Importantly,
UNC9975 displayed potent antipsychotic-like activity without
inducing motoric side effects in inbred C57BL/6 mice in vivo.
Genetic deletion of β-arrestin-2 simultaneously attenuated
the antipsychotic actions of UNC9975 and transformed it into
a typical antipsychotic drug with a high propensity to induce
catalepsy.
Similarly, the antipsychotic-like activity displayed by
UNC9994, an extremely β-arrestin-biased D2R agonist, in wildtype mice was completely abolished in β-arrestin-2 knockout
mice. These results suggest that β-arrestin signaling and
recruitment can be simultaneously a significant contributor
to antipsychotic efficacy and protective against motoric side
effects [42]. Follow-up comprehensive structure-functional
selectivity relationship studies (SFSR) focused on four regions
of aripiprazole scaffold (e.g. left hand side phenyl region,
middle amino region, central linker region, and right hand side
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bicyclic aromatic region) resulted in more β-arrestin biased D2R
agonists [43].

This combined medicinal chemistry and pharmacological
profiling approach also provided the biomedical community a
successful proof-of-concept for how functionally selective ligands
can be discovered. The study designed to test the effectiveness
of UNC9975 or UNC9994 on schizophrenia-like behaviors in
phencyclidine treated or NR1-knockdown hypoglutamatergic
mice showed that the UNC compounds reduced hyper
locomotion in the open field, restored PPI, improved novel
object recognition memory, partially normalized social behavior,
decreased conditioned avoidance responding, and elicit a much
lower level of catalepsy than haloperidol [44]. These preclinical
results suggest that exploitation of functional selectivity may
provide unique opportunities to develop drugs with fewer side
effects, greater therapeutic selectivity, and enhanced efficacy for
treating schizophrenia and related conditions than medications
that are currently available.

Cariprizine (5) and analogs (Compounds 6 And 7)

Cariprazine (5) is an atypical antipsychotic recently approve
by FDA for the treatment of schizophrenia and bipolar mania
[45]. It acts primarily as a partial agonist for D2R and D3R [46]
with higher selectivity for D3R [46,47]. The structure-functional
selectivity relationship (SFSR) studies of cariprazine scaffold
carried out by Shonberg and colleagues at Monash University
was focused on three main portions of the lead compound:
the tertiary amine containing “head group”, the cyclohexylene
“spacer” group, and the tert-butyl carbamate “tail group” [48].

Similar to the SFSR studies of aripiprazole analogs, to assess
G protein-related signaling, the compounds were profiled in
the D2 CAMP accumulation assay, whereas β-arrestin signaling
was evaluated by measuring phosphorylation of extracellular
signal-regulated kinase 1/2 (ERK 1/2). In this testing paradigm,
cariprazine (5) displayed a 230-fold bias toward the cAMP
pathway compared with dopamine. Interestingly, while all
cariprazine derivatives disclosed in this letter showed a bias
toward the G protein signaling pathway (6), subtle changes
of the D2 unbiased partial agonist, a structurally related aryl
piperazine reported by Tschammer [49], led to analogues that
displayed a strong bias toward β-arrestin signaling such as
compound 7. By combining the medicinal chemistry efforts with
novel analytical pharmacology methods [50], it was discovered
that the nature of the head group, the composition of the tail
group, and the orientation, length, and flexibility of the spacer
were all important factors for the control of functional selectivity
at the D2R [48].

Functional selective D2R ligands with privileged
structures (compound 8)

Another comprehensive structure activity relationship
(SAR) studies carried out by Szabo and colleagues at Monash
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University also led to the discovery of novel functional selective
D2R ligands [51]. They investigated the determinants of
efficacy, affinity, and bias for three privileged structures for
the D2R, exploring changes to linker length and incorporation
of a heterocyclic unit. After profiling the newly synthesized
compounds in two signaling assays (CAMP and pERK1/2), they
were able to identify and quantify determinants of functional
selectivity at the D2R. The results from combined medicinal
chemistry and pharmacological profiling approach revealed
that: 1) substitution on the phenylpiperazine privileged
structures (2-methoxy vs 2,3-dichloro) influenced bias when the
thienopyridine heterocycle was absent; and 2) upon inclusion of
the thienopyridine unit, the substitution pattern (4,6-dimethyl
vs 5-chloro-6-methoxy-4-methyl) had a significant effect on bias
that overruled the effect of the phenylpiperazine substitution
pattern [51]. This latter observation could be reconciled with
an extended binding mode for these compounds, whereby the
interaction of the heterocycle with a secondary binding pocket
may bring functional selectivity to the parent compounds. The
resulted novel D2R partial agonists, 8 and 9, display a similar
affinity for the D2R as aripiprazole but exhibit distinct functional
selectivity profiles, which made them useful tools to explore the
contribution of functional selectivity to antipsychotic efficacy.

Functional selective D2R/D3R partial agonists

Dopamine D2R and D3R are known as valuable targets
for the treatment of neurological and psychiatric disorders
including schizophrenia [52-54]. Hiller and colleagues evaluated
a series of newly synthesized compounds for their ability to
differentially activate distinct signaling pathways [55].
Measurement of D2L- and D2S-mediated [35S] GTPγS
incorporation in the presence of coexpressed Gαo and Gαi
subunits showed significantly biased receptor activation for
several test compounds [55]. A follow-up study from the same
group using the same evaluation methods yielded the most
striking functionally selective D2R ligand, carbaldoxime 8b (9,
Gαo1, pEC50 = 8.87, Emax = 65%; Gαi2, pEC50 = 6.63, Emax=27%)
[56]. It was also indicated in the study that 1,4-disubstituted
aromatic piperazines (1,4-DAPs) behaved as antagonists for
β-arrestin-2 recruitment, implying significant ligand bias for
G-protein activation over β-arrestin-2 recruitment at D2R.
Regiochemistry and the nature of functional groups attached to
the pyrazolo [1,5-a]pyridine moiety strongly influence ligand
efficacy and selectivity between D2R and D3R activation [56].

Other functional selective D2 ligands

Intensive structural exploration on aripiprazole scaffold
engendered UNC2438 (10) which was found to be a G-protein
biased compounds [57]. Further structure-functional selectivity
relationship studies (SFSR) on UNC2438 focused on the
right hand side benzothiazole moiety and the left hand side
phenylpiperazine moiety furnished a few additional G-protein
biased compounds which were partial agonists in D2R Gio-
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mediated CAMP inhibition assay and simultaneously inactive in
D2R-mediated β-arrestin-2 recruitment assay [57].

Most recently, a tailored virtual library with close to 13,000
compounds bearing 2,3-dichlorophenylpiperazine, a privileged
orthosteric scaffold, connected to diverse chemical moieties via
a linker was docked to the D2R model [58]. Eighteen top-ranked
compounds that occupied both the orthosteric and allosteric site
were synthesized, leading to the discovery of 16 partial agonists.
While a majority of the ligands had comparable maximum
effects in the G protein and β-arrestin recruitment assays,
some displayed preference for a single pathway. In particular,
compound 11 stimulated β-arrestin recruitment (EC50 = 320
nM, Emax = 16%) but had no detectable G protein signaling.

Conclusion

The growing realization of the complexity of G protein
coupled receptor (GPCR) mediated signal transduction pathways,
specifically D2R mediated signaling pathways, has provided
a theoretical framework for the development of functionally
selective or biased ligands. Several studies have demonstrated
that agonists differ in their ability to activate various pathways.
Notably, blockade of β-arrest in recruitment was found to be a
shared property of antipsychotics that exhibit either antagonist
(e.g., haloperidol), or partial agonist (e.g., aripiprazole) activity
through Gai/o-CAMP pathways [28]. In contrast, a study with
analogs of the novel antipsychotic aripiprazole suggested that
D2 ligands with Gai/o antagonist and β-arrestin agonist activity
may have antipsychotic behavioral activity with reduced extra
pyramidal side effects in a mouse model [3]. While there are
still a lot of questions to be answered in this field, heightened
awareness of the potential benefit of pathway biased D2R ligands
has inspired scientists in this area develop more functionally
selective D2R ligands as better antipsychotic therapies for
schizophrenia.
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